4DMT Announces New Employment Inducement Grants
4D Molecular Therapeutics uses inducement RSU grants under Nasdaq rules to attract seven new non-executive employees.
Rhea-AI Summary
4D Molecular Therapeutics (FDMT) granted equity awards to new employees on September 8, 2026. The compensation committee approved a total of 96,000 Restricted Stock Units (RSUs) for seven new non-executive employees as employment inducement awards.
The RSUs were issued under the company’s 2025 Employment Inducement Award Plan, as amended, and are intended to qualify under Rule 5635(c)(4) of The Nasdaq Global Market, which permits equity grants used to induce individuals to enter into employment with the company.
Positive
- None.
Negative
- None.
Key Figures
- Restricted stock units
- 96,000 RSUs
- Granted to seven new non-executive employees
- Recipients
- 7 employees
- New non-executive employees
Historical Context
-
Five new employees received 35,200 RSUs under the 2025 inducement plan
-
Six new employees received 37,900 RSUs under the 2025 inducement plan
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
restricted stock units financial
AI-generated analysis. How Rhea-AI works. Not financial advice.
EMERYVILLE, Calif., Sept. 11, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients, today announced that on September 8, 2026, the compensation committee of the Company’s board of directors granted seven new non-executive employees 96,000 Restricted Stock Units (RSUs). The RSUs were granted pursuant to the Company’s 2025 Employment Inducement Award Plan, as amended, under Rule 5635(c)(4) of The Nasdaq Global Market for equity grants to induce new employees to enter into employment with the Company.
About 4DMT
4DMT is a leading late-stage biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. The Company’s lead product candidate 4D-150 is designed to be a backbone therapy forming the foundation of treatment of blinding retinal vascular diseases by providing multi-year sustained delivery of anti-VEGF biologics (aflibercept and anti-VEGF-C) with a single intravitreal injection, which substantially reduces the treatment burden associated with current bolus injections. The Company’s lead indication for 4D-150 is wet age-related macular degeneration, which is currently in Phase 3 development, and second indication is diabetic macular edema. The Company’s second product candidate is 4D-710, which is the first known genetic medicine to demonstrate successful delivery and expression of the CFTR transgene in the lungs of people with cystic fibrosis after aerosol delivery. 4D Molecular Therapeutics™, 4DMT™, Therapeutic Vector Evolution™, Backbone 4 Retina™ and the 4DMT logo are trademarks of 4DMT.
All of the Company’s product candidates are in clinical or preclinical development and have not yet been approved for marketing by the U.S. Food and Drug Administration or any other regulatory authority. No representation is made as to the safety or effectiveness of the Company’s product candidates for the therapeutic uses for which they are being studied.
Learn more at www.4DMT.com and follow us on LinkedIn.
Contacts: Media: Jenn Gordon dna Communications Media@4DMT.com Investors: Julian Pei Head of Investor Relations and Strategic Finance Investor.Relations@4DMT.com